Lyell Immunopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	145.93	123.83	294.29	140.87	98.47
Short-Term Investments	400.58	516.6	320.97	472.21	339.38
Cash & Cash Equivalents	546.51	640.43	615.26	613.09	437.85
Cash Growth	-14.67%	4.09%	0.35%	40.02%	-
Other Current Assets	8.18	10.86	11.03	4.46	2.41
Total Current Assets	554.69	651.3	626.29	617.55	440.26
Property, Plant & Equipment	142.32	166.27	166.64	124.06	43.71
Long-Term Investments	48.51	115.04	330.53	163.44	68.98
Other Long-Term Assets	4.52	4.96	3.95	3.24	2.68
Total Long-Term Assets	195.34	286.27	501.12	290.73	115.37
Total Assets	750.03	937.56	1,127	908.28	555.63
Accounts Payable	4.82	3.92	3.21	9.4	2.84
Deferred Revenue	0	0	84.65	95.16	102.92
Other Current Liabilities	29.7	33.11	-41.12	-55.27	-83.72
Total Current Liabilities	34.52	37.03	46.74	49.29	22.05
Long-Term Debt	56.89	63.17	66.65	50.96	27.13
Other Long-Term Liabilities	3.66	4.11	84.23	89.6	98.41
Total Long-Term Liabilities	60.56	67.28	150.88	140.56	125.53
Total Liabilities	95.08	104.31	197.62	189.84	147.58
Total Debt	56.89	63.17	66.65	50.96	27.13
Debt Growth	-9.93%	-5.22%	30.80%	87.86%	-
Retained Earnings	-1,002.11	-767.48	-584.36	-334.14	-129.67
Comprehensive Income	-0.09	-7.6	-1.62	0.26	0.45
Shareholders' Equity	654.95	833.25	929.79	-292.53	-111.11
Net Cash / Debt	489.61	577.26	548.61	562.13	410.72
Net Cash / Debt Growth	-15.18%	5.22%	-2.40%	36.86%	-
Net Cash Per Share	1.95	2.34	4.04	42.40	75.65
Working Capital	520.17	614.27	579.55	568.26	418.21
Book Value Per Share	2.61	3.37	6.84	-22.06	-20.47

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).